Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.
The U.S. FDA declined to approve Acer Therapeutics Inc.’s Edsivo for a severe, rare genetic disorder – vascular Ehlers-Danlos syndrome (vEDS) – that can cause blood vessels to fatally rupture.
The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.
